|(G;G)||1.1||among NSCLC patients, better Gefitinib response; common|
In a study of therapeutic outcome and survival in 84 advanced non-small-cell lung cancer (NSCLC) patients treated with Gefitinib, the response rate for rs2293347(G;G) patients was almost double that of other genotypes for this SNP (71.2% versus 37.5%, p=0.0043). The rs2293347(G;G) genotype was also associated with longer progression-free survival compared with the rs2293347(A;G) or (A;A) genotypes (11 months versus 3 months, p=0.0018).[PMID 19201048]
[PMID 17956637] Polymorphisms in the epidermal growth factor receptor gene and the risk of primary lung cancer: a case-control study.
[PMID 19190167] A two-stage case-control study of EGFR polymorphisms and breast cancer risk.
[PMID 19372140] EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis.
[PMID 19641380] Candidate gene polymorphisms for diabetes mellitus, cardiovascular disease and cancer are associated with longevity in Koreans.
[PMID 21859544] [Effect of rs2293347 Polymorphism in EGFR on the Clinical Efficacy of Gefitinib in Patients with Non-small Cell Lung Cancer].
[PMID 22552271] Integrated effect of EGFR and PAR-1 signaling crosstalk on airway hyperresponsiveness
[PMID 23313300] Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib.
[PMID 23816762] Identification of a candidate single-nucleotide polymorphism related to chemotherapeutic response through a combination of knowledge-based algorithm and hypothesis-free genomic data.